HEARTSTOP 3,154 Posted August 29, 2020 Share Posted August 29, 2020 "After the 2003 outbreak of severe acute respiratory syndrome (SARS), researchers developed an antiviral drug that proved to be effective against feline coronavirus (FCoV), which sometimes leads to feline infectious peritonitis (FIP), an often fatal disease in cats. Now it appears that the antiviral drug, a dipeptide-based protease inhibitor, may benefit COVID-19 patients. The new findings are being reported by scientists at the University of Alberta (U of A), one of whom was also involved in the earliest work on the antiviral drug. This scientist, John C. Vederas, PhD, professor of chemistry, is a corresponding author of a paper (“Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication”) that appeared August 27 in Nature Communications. Actually, the findings first appeared May 4 on BioRxIV, a research website. But the scientists could hardly be accused of letting the cat out of the bag. “There’s a rule with COVID research that all results need to be made public immediately,” said Lemieux, which is why the findings were posted before being published in a peer-reviewed journal. “In just two months, our results have shown that the drug is effective at inhibiting viral replication in cells with SARS-CoV-2”, Lemieux asserted. “This drug is very likely to work in humans, so we’re encouraged that it will be an effective antiviral treatment for COVID-19 patients.” The U of A researchers are preparing to launch clinical trials of the drug. In the meantime, they will continue to test modifications of the drug. “We determined the three-dimensional shape of the protease with the drug in the active site pocket, showing the mechanism of inhibition,” she explained. “This will allow us to develop even more effective drugs.” She added, however, that the current drug shows enough antiviral action against SARS-CoV-2 to proceed immediately to clinical trials. The researchers have established a collaboration with Anivive Life Sciences, a veterinary medicine company that is developing the drug for cats, to produce the quality and quantity of drug needed for human clinical trials. Lemieux said it will likely be tested in Alberta in combination with other promising antivirals such as remdesivir, the first treatment approved for conditional use in some countries including the United States and Canada. “Typically for a drug to go into clinical trials, it has to be confirmed in the lab and then tested in animal models,” Lemieux emphasized. “Because this drug has already been used to treat cats with coronavirus, and it’s effective with little to no toxicity, it’s already passed those stages, and this allows us to move forward.”" Source: https://www.genengnews.com/news/cat-got-your-sars-cov-2-antiviral/ So basically, we could have a PrEP/PEP type of drug for Covid-19 very soon. Thoughts? IDGAF Link to post Share on other sites More sharing options...
Doot 2 Posted August 29, 2020 Share Posted August 29, 2020 I'd save my cats before I save myself from this virus. #SaveTheKitties Link to post Share on other sites More sharing options...
Featured Posts
Archived
This topic is now archived and is closed to further replies.